Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Analysis of Host Responses to Neisseria gonorrhoeae Using a Human Three-Dimensional Endometrial Epithelial Cell Model.

Łaniewski P, Herbst-Kralovetz MM.

Methods Mol Biol. 2019;1997:347-361. doi: 10.1007/978-1-4939-9496-0_20.

PMID:
31119633
2.

Chronic immune barrier dysregulation among women with a history of violence victimization.

Swaims-Kohlmeier A, Haddad LB, Li ZT, Brookmeyer KA, Baker JM, Widom CS, Lamousin JC, Chi KH, Chen CY, Kersh EN, Johnson JA, Herbst-Kralovetz MM, Hogben M, Ofotokun I, Kohlmeier JE.

JCI Insight. 2019 May 16;4(10). pii: 126097. doi: 10.1172/jci.insight.126097. eCollection 2019 May 16.

3.

Features of the cervicovaginal microenvironment drive cancer biomarker signatures in patients across cervical carcinogenesis.

Łaniewski P, Cui H, Roe DJ, Barnes D, Goulder A, Monk BJ, Greenspan DL, Chase DM, Herbst-Kralovetz MM.

Sci Rep. 2019 May 14;9(1):7333. doi: 10.1038/s41598-019-43849-5.

4.

Deciphering the complex interplay between microbiota, HPV, inflammation and cancer through cervicovaginal metabolic profiling.

Ilhan ZE, Łaniewski P, Thomas N, Roe DJ, Chase DM, Herbst-Kralovetz MM.

EBioMedicine. 2019 Jun;44:675-690. doi: 10.1016/j.ebiom.2019.04.028. Epub 2019 Apr 24.

5.

IL-36γ induces a transient HSV-2 resistant environment that protects against genital disease and pathogenesis.

Gardner JK, Herbst-Kralovetz MM.

Cytokine. 2018 Nov;111:63-71. doi: 10.1016/j.cyto.2018.07.034. Epub 2018 Aug 15.

PMID:
30118914
6.

Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women.

Łaniewski P, Barnes D, Goulder A, Cui H, Roe DJ, Chase DM, Herbst-Kralovetz MM.

Sci Rep. 2018 May 15;8(1):7593. doi: 10.1038/s41598-018-25879-7.

7.

Microbiota-drug interactions: Impact on metabolism and efficacy of therapeutics.

Wilkinson EM, Ilhan ZE, Herbst-Kralovetz MM.

Maturitas. 2018 Jun;112:53-63. doi: 10.1016/j.maturitas.2018.03.012. Epub 2018 Apr 5. Review.

PMID:
29704918
8.

Uterine Microbiota: Residents, Tourists, or Invaders?

Baker JM, Chase DM, Herbst-Kralovetz MM.

Front Immunol. 2018 Mar 2;9:208. doi: 10.3389/fimmu.2018.00208. eCollection 2018. Review.

9.

Estrogen-gut microbiome axis: Physiological and clinical implications.

Baker JM, Al-Nakkash L, Herbst-Kralovetz MM.

Maturitas. 2017 Sep;103:45-53. doi: 10.1016/j.maturitas.2017.06.025. Epub 2017 Jun 23. Review.

PMID:
28778332
10.

Human Three-Dimensional Endometrial Epithelial Cell Model To Study Host Interactions with Vaginal Bacteria and Neisseria gonorrhoeae.

Łaniewski P, Gomez A, Hire G, So M, Herbst-Kralovetz MM.

Infect Immun. 2017 Feb 23;85(3). pii: e01049-16. doi: 10.1128/IAI.01049-16. Print 2017 Mar.

11.

Three-Dimensional Rotating Wall Vessel-Derived Cell Culture Models for Studying Virus-Host Interactions.

Gardner JK, Herbst-Kralovetz MM.

Viruses. 2016 Nov 9;8(11). pii: E304. Review.

12.

Menopause and the vaginal microbiome.

Muhleisen AL, Herbst-Kralovetz MM.

Maturitas. 2016 Sep;91:42-50. doi: 10.1016/j.maturitas.2016.05.015. Epub 2016 Jun 1. Review.

PMID:
27451320
13.

New Systems for Studying Intercellular Interactions in Bacterial Vaginosis.

Herbst-Kralovetz MM, Pyles RB, Ratner AJ, Sycuro LK, Mitchell C.

J Infect Dis. 2016 Aug 15;214 Suppl 1:S6-S13. doi: 10.1093/infdis/jiw130. Review.

14.

IL-36γ Augments Host Defense and Immune Responses in Human Female Reproductive Tract Epithelial Cells.

Winkle SM, Throop AL, Herbst-Kralovetz MM.

Front Microbiol. 2016 Jun 17;7:955. doi: 10.3389/fmicb.2016.00955. eCollection 2016.

15.

Antimicrobial peptides in the female reproductive tract: a critical component of the mucosal immune barrier with physiological and clinical implications.

Yarbrough VL, Winkle S, Herbst-Kralovetz MM.

Hum Reprod Update. 2015 May-Jun;21(3):353-77. doi: 10.1093/humupd/dmu065. Epub 2014 Dec 29. Review.

PMID:
25547201
16.

Overcoming barriers in the mucosal delivery of virus-like particle-based vaccines.

Herbst-Kralovetz MM.

Ther Deliv. 2014 Jul;5(7):741-4. doi: 10.4155/tde.14.52. No abstract available.

PMID:
25287380
17.

Norovirus Narita 104 virus-like particles expressed in Nicotiana benthamiana induce serum and mucosal immune responses.

Mathew LG, Herbst-Kralovetz MM, Mason HS.

Biomed Res Int. 2014;2014:807539. doi: 10.1155/2014/807539. Epub 2014 May 11.

18.

Bacteria in the vaginal microbiome alter the innate immune response and barrier properties of the human vaginal epithelia in a species-specific manner.

Doerflinger SY, Throop AL, Herbst-Kralovetz MM.

J Infect Dis. 2014 Jun 15;209(12):1989-99. doi: 10.1093/infdis/jiu004. Epub 2014 Jan 7.

PMID:
24403560
19.

TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccines.

Hjelm BE, Kilbourne J, Herbst-Kralovetz MM.

Hum Vaccin Immunother. 2014;10(2):410-6. doi: 10.4161/hv.27147. Epub 2013 Nov 26.

20.

Lack of norovirus replication and histo-blood group antigen expression in 3-dimensional intestinal epithelial cells.

Herbst-Kralovetz MM, Radtke AL, Lay MK, Hjelm BE, Bolick AN, Sarker SS, Atmar RL, Kingsley DH, Arntzen CJ, Estes MK, Nickerson CA.

Emerg Infect Dis. 2013 Mar;19(3):431-8. doi: 10.3201/eid1903.121029.

21.

Microbial products alter the expression of membrane-associated mucin and antimicrobial peptides in a three-dimensional human endocervical epithelial cell model.

Radtke AL, Quayle AJ, Herbst-Kralovetz MM.

Biol Reprod. 2012 Dec 6;87(6):132. doi: 10.1095/biolreprod.112.103366. Print 2012 Jun.

22.

Intranasal vaccination with murabutide enhances humoral and mucosal immune responses to a virus-like particle vaccine.

Jackson EM, Herbst-Kralovetz MM.

PLoS One. 2012;7(7):e41529. doi: 10.1371/journal.pone.0041529. Epub 2012 Jul 25.

23.

Culturing and applications of rotating wall vessel bioreactor derived 3D epithelial cell models.

Radtke AL, Herbst-Kralovetz MM.

J Vis Exp. 2012 Apr 3;(62). pii: 3868. doi: 10.3791/3868.

24.

A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge.

Phoolcharoen W, Dye JM, Kilbourne J, Piensook K, Pratt WD, Arntzen CJ, Chen Q, Mason HS, Herbst-Kralovetz MM.

Proc Natl Acad Sci U S A. 2011 Dec 20;108(51):20695-700. doi: 10.1073/pnas.1117715108. Epub 2011 Dec 5.

25.

Plant-derived antigens as mucosal vaccines.

Mason HS, Herbst-Kralovetz MM.

Curr Top Microbiol Immunol. 2012;354:101-20. doi: 10.1007/82_2011_158. Review.

PMID:
21811930
26.

Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine.

Velasquez LS, Shira S, Berta AN, Kilbourne J, Medi BM, Tizard I, Ni Y, Arntzen CJ, Herbst-Kralovetz MM.

Vaccine. 2011 Jul 18;29(32):5221-31. doi: 10.1016/j.vaccine.2011.05.027. Epub 2011 Jun 2.

27.

An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles.

Velasquez LS, Hjelm BE, Arntzen CJ, Herbst-Kralovetz MM.

Clin Vaccine Immunol. 2010 Dec;17(12):1850-8. doi: 10.1128/CVI.00230-10. Epub 2010 Oct 20.

28.

Organotypic 3D cell culture models: using the rotating wall vessel to study host-pathogen interactions.

Barrila J, Radtke AL, Crabbé A, Sarker SF, Herbst-Kralovetz MM, Ott CM, Nickerson CA.

Nat Rev Microbiol. 2010 Nov;8(11):791-801. doi: 10.1038/nrmicro2423. Review.

PMID:
20948552
29.

Development and characterization of a three-dimensional organotypic human vaginal epithelial cell model.

Hjelm BE, Berta AN, Nickerson CA, Arntzen CJ, Herbst-Kralovetz MM.

Biol Reprod. 2010 Mar;82(3):617-27. doi: 10.1095/biolreprod.109.080408. Epub 2009 Dec 9.

30.

Quantification and comparison of toll-like receptor expression and responsiveness in primary and immortalized human female lower genital tract epithelia.

Herbst-Kralovetz MM, Quayle AJ, Ficarra M, Greene S, Rose WA 2nd, Chesson R, Spagnuolo RA, Pyles RB.

Am J Reprod Immunol. 2008 Mar;59(3):212-24. doi: 10.1111/j.1600-0897.2007.00566.x. Epub 2008 Jan 12.

PMID:
18201283
31.

Supplemental Content

Loading ...
Support Center